Novo Nordisk has unveiled significant advancements in obesity treatment with the phase 3b STEP UP trial, showcasing the efficacy of a higher dose of Wegovy® (semaglutide 7.2 mg). The trial, conducted in Bagsvaerd, Denmark, demonstrated that participants receiving the increased dosage experienced an average weight loss of 21%, with one-third achieving a reduction of 25% or more compared to those on a placebo.
Enhanced Weight Loss Outcomes
The STEP UP trial focused on individuals with obesity but without diabetes, spanning 72 weeks. Participants on the semaglutide 7.2 mg regimen not only surpassed the 20% weight loss mark but also maintained a robust safety profile consistent with the previously approved 2.4 mg dose. These results position Wegovy® as a potent option for those struggling to reach their weight management goals through existing treatments.
Safety and Tolerability Maintained
The higher dosage maintained a safety and tolerability profile in line with existing semaglutide treatments. The majority of adverse events were mild to moderate gastrointestinal issues, which subsided over time. Only a small percentage of participants discontinued treatment due to these side effects, underscoring the drug’s overall acceptability among users.
- Semaglutide 7.2 mg led to a 21% average weight loss compared to 2.4% with placebo.
- 33.2% of participants lost 25% or more of their body weight.
- The safety profile remained consistent with higher doses, primarily involving mild gastrointestinal issues.
- Over 90% of participants achieved at least a 5% weight loss on the higher dose.
The STEP UP trial not only reinforces the substantial weight loss potential of semaglutide but also expands the therapeutic options available for obesity management. Novo Nordisk plans to seek regulatory approval for the higher dose in the EU and other markets, potentially offering a more effective treatment avenue for patients requiring significant weight reduction.
As obesity continues to pose a major public health challenge, the introduction of higher-dose semaglutide provides a promising development. Healthcare providers may have a more powerful tool in their arsenal to help patients achieve and sustain meaningful weight loss, potentially reducing the risk of associated comorbidities such as heart disease and type 2 diabetes.
Looking ahead, the prospect of an oral formulation of Wegovy® could revolutionize accessibility and ease of administration, further enhancing patient adherence and outcomes. This advancement aligns with Novo Nordisk’s commitment to innovating and addressing the diverse needs of individuals battling obesity.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
